A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer include androgen deprivation therapy (ADT) combined with chemotherapy or ...

Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate cancer (mHSPC) involves considering factors such as disease burden, patient ...

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...

A panelist discusses how comprehensive molecular testing at MBC diagnosis, including genomic profiling and ESR1 mutation status, helps guide treatment decisions and identify potential therapeutic ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Panelists discuss how mutational burden influences the duration of response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), as observed in the COMMANDS trial (Komrokji et al ...

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

Martin Dreyling, MD, University Hospital LMU Munich, in Germany, discusses the final follow-up results of the TRIANGLE study ...

In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed ...